Germany's STADA Arz posts strong first-quarter 2010 results, despite difficult climate
German generics drugmaker STADA Arzneimittel, which has become the object of takeover speculation after US behemoth Pfizer lost out in the fight to acquire Ratiopharm to Teva, has published strong financial results for the first quarter of 2010.
Group sales rose by 5% to 395.7 million euros ($500.6 million), due in particular to the firm's international sales which, in the first quarter of 2010, made up a total of 64% of group revenues and increased 11% to 252.3 million euros. EBITDA was up 12% for the quarter at 75.8 million euros and net income advanced 17% to 28.1 million euros.
"Despite the ongoing difficult framework conditions in various national markets, the key earnings figures of the first quarter are in the upper end of our expectations. We can therefore talk about a very good result in the first quarter", was the positive comment of Hartmut Retzlaff, chairman of the executive board of STADA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze